Literature DB >> 16875495

Alterations of p53, BCL-2, and hMSH2 protein expression in the normal brain tissues, gliosis, and gliomas.

Mahmoud R Hussein1, Rabab M H El-Ghorori, Yasser G Abd El-Rahman.   

Abstract

Tumorigenesis involves alterations in the tumor suppressor genes (p53), protooncogenes (BCL-2), and housekeeping genes (human MutS homologue-2 (hMSH2). We hypothesized that development of gliomas is associated with alterations of p53, BCL-2, and hMSH2 protein expression. To test our hypothesis and to examine these issues, we immunostained 60 specimens entailing normal brain tissues, gliosis, and gliomas (Grade I, II, III, IV) for p53, BCL-2, and hMSH2 protein expression. As compared with the normal brain and gliosis, examination of the average weighted scores in gliomas (Grade I, II, III, IV, respectively) showed significant up-regulation of: (i) p53 protein (0.0 +/- 0.0; 0.0 +/- 0.0; 0.9 +/- 0.5; 1.6 +/- 0.8; 1.7 +/- 0.5; and 4.1 +/- 0.8, P < 0.0001) (ii) hMSH2 (1.3 +/- 0.3; 1.5 +/- 0.7; 1.9 +/- 1.1; 2.2 +/- 0.5; 4.1 +/- 1.5; and 4.7 +/- 1.1, P < 0.0006), and (iii) BCL-2 (0.8 +/- 0.5; 1.9 +/- 0.5; 1.9 +/- 0.6; 2.0 +/- 0.6; 4.4 +/- 1.2; and 4.6 +/- 0.8, P < 0.001). The expression values (p53, BCL-2, and hMSH2) were statistically significantly higher (P < 0.05) in astrocytomas (Grade III) than in other gliomas. There was an insignificant negative correlation between p53 and BCL-2 (r = -0.07, P > 0.05) and between p53 and hMSH2 (r = -0.08, P > 0.05) protein expression. Alterations of the p53, BCL-2, and hMSH2 proteins occur during the development of these tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16875495      PMCID: PMC2517375          DOI: 10.1111/j.1365-2613.2006.00482.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  34 in total

1.  BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study.

Authors:  L Rieger; M Weller; A Bornemann; M Schabet; J Dichgans; R Meyermann
Journal:  J Neurol Sci       Date:  1998-02-18       Impact factor: 3.181

2.  Microsatellite instability and the PTEN1 gene mutation in a subset of early onset gliomas carrying germline mutation or promoter methylation of the hMLH1 gene.

Authors:  M Kanamori; H Kon; T Nobukuni; S Nomura; K Sugano; S Mashiyama; T Kumabe; T Yoshimoto; M Meuth; T Sekiya; Y Murakami
Journal:  Oncogene       Date:  2000-03-16       Impact factor: 9.867

3.  Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions.

Authors:  H Yaziji; R Massarani-Wafai; M Gujrati; J G Kuhns; A W Martin; J C Parker
Journal:  Am J Surg Pathol       Date:  1996-09       Impact factor: 6.394

4.  p53 in nonneoplastic central nervous system lesions: an immunohistochemical and genetic sequencing study.

Authors:  Ozlem Kurtkaya-Yapicier; Bernd W Scheithauer; Deanne Hebrink; Charles D James
Journal:  Neurosurgery       Date:  2002-11       Impact factor: 4.654

5.  The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship?

Authors:  Mahmoud R Hussein
Journal:  Tumour Biol       Date:  2004 Jul-Aug

6.  Analysis of 2 antiapoptotic factors in gliomas: bcl-2 overexpression and p53 mutations.

Authors:  C Rodriguez-Pereira; J M Suarez-Peñaranda; F Barros; M J Sobrido; M Vazquez-Salvado; J Forteza
Journal:  Arch Pathol Lab Med       Date:  2001-02       Impact factor: 5.534

7.  Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in astrocytic gliomas and their correlation to cell proliferation.

Authors:  K Dietzmann; P von Bossanyi; J Sallaba; E Kirches; H J Synowitz; M Warich-Kirches
Journal:  Gen Diagn Pathol       Date:  1996-05

8.  Microsatellite instability and mutation of DNA mismatch repair genes in gliomas.

Authors:  S Y Leung; T L Chan; L P Chung; A S Chan; Y W Fan; K N Hung; W K Kwong; J W Ho; S T Yuen
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

9.  Human gliomas with wild-type p53 express bcl-2.

Authors:  L M Alderson; R L Castleberg; G R Harsh; D N Louis; J W Henson
Journal:  Cancer Res       Date:  1995-03-01       Impact factor: 12.701

10.  Association of p53 tumor suppressor gene with paraclinical and clinical modalities of gliomas patients in Malaysia.

Authors:  A A Yusoff; J Abdullah; M R Abdullah; A R Mohd Ariff; M N Isa
Journal:  Acta Neurochir (Wien)       Date:  2004-04-08       Impact factor: 2.216

View more
  10 in total

1.  Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways.

Authors:  Chen Mo; Yumei Dai; Ning Kang; Lianxian Cui; Wei He
Journal:  J Biol Chem       Date:  2012-04-09       Impact factor: 5.157

Review 2.  The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer.

Authors:  Markus Seifert; Jörg Reichrath
Journal:  J Mol Histol       Date:  2006-11-02       Impact factor: 2.611

3.  Long intergenic non-protein coding RNA 00475 silencing acts as a tumor suppressor in glioma under hypoxic condition by impairing microRNA-449b-5p-dependent AGAP2 up-regulation.

Authors:  Lei Yu; Si Gui; Yawei Liu; Xiaoyu Qiu; Binghui Qiu; Xi'an Zhang; Jun Pan; Jun Fan; Songtao Qi; Guozhong Zhang
Journal:  Ther Adv Med Oncol       Date:  2020-08-11       Impact factor: 8.168

4.  Predictive Role of p53 Protein as a Single Marker or Associated to Ki67 Antigen in Oral Carcinogenesis.

Authors:  L Montebugnoli; L Felicetti; D B Gissi; F Cervellati; D Servidio; C Marchetti; C Prati; F Flamminio; M P Foschini
Journal:  Open Dent J       Date:  2008-02-21

5.  Predictive Role of p53 Protein as a Single Marker or Associated with ki67 Antigen in Oral Leukoplakia: A Retrospective Longitudinal Study.

Authors:  Davide B Gissi; Andrea Gabusi; Dora Servidio; Fabio Cervellati; Lucio Montebugnoli
Journal:  Open Dent J       Date:  2015-01-30

6.  Integrated analysis of mismatch repair system in malignant astrocytomas.

Authors:  Irene Rodríguez-Hernández; Juan Luis Garcia; Angel Santos-Briz; Aurelio Hernández-Laín; Jose María González-Valero; Juan Antonio Gómez-Moreta; Oscar Toldos-González; Juan Jesús Cruz; Javier Martin-Vallejo; Rogelio González-Sarmiento
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

7.  MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-κB1/MMP9 signaling pathway.

Authors:  Tian-Quan Yang; Xiao-Jun Lu; Ting-Feng Wu; Da-Dong Ding; Zhao-Hui Zhao; Gui-Lin Chen; Xue-Shun Xie; Bin Li; Yong-Xin Wei; Ling-Chuan Guo; Yu Zhang; Yu-Lun Huang; You-Xin Zhou; Zi-Wei Du
Journal:  Cancer Sci       Date:  2014-02-11       Impact factor: 6.716

8.  Nuclear factor-kappa B1 inhibits early apoptosis of glioma cells by promoting the expression of Bcl-2.

Authors:  Tian-Quan Yang; Min Chen; Yong-Qiang Wang; Wei Xu; Yong Han; Jin Xu; Yong-Jun Xiang; Bin Yuan; Hang-Zhou Wang; You-Xin Zhou
Journal:  Onco Targets Ther       Date:  2017-08-31       Impact factor: 4.147

Review 9.  MicroRNA based theranostics for brain cancer: basic principles.

Authors:  George E D Petrescu; Alexandru A Sabo; Ligia I Torsin; George A Calin; Mihnea P Dragomir
Journal:  J Exp Clin Cancer Res       Date:  2019-05-29

10.  NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways.

Authors:  Naze G Avci; Sadaf Ebrahimzadeh-Pustchi; Yasemin M Akay; Yoshua Esquenazi; Nitin Tandon; Jay-Jiguang Zhu; Metin Akay
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.